FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
NEW YORK, Dec. 22, 2016 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Xerox Corporation common stock (NYSE:XRX) from April 23, 2012 through October 23, 2015, both dates inclusive (the “Class Period”) of the important December 23, 2016 lead plaintiff deadline the in the class action. The lawsuit seeks to recover damages for Xerox investors under the federal securities laws.
To join the Xerox class action, go to http://www.rosenlegal.com/cases-972.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Xerox’s existing Health Enterprise projects were experiencing major delays and cost overruns; (2) Xerox would be unable to deliver Health Enterprise implementations at sustainable profits; and (3) as a result, Xerox’s positive statements about its business, operations, and prospects lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 23, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-972.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected]. Attorney Advertising. Prior results do not guarantee a similar outcome.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
